--- title: "Assessing L'Oréal (ENXTPA:OR) Valuation After Recent Share Price Weakness" type: "News" locale: "en" url: "https://longbridge.com/en/news/286430983.md" description: "L'Oréal's stock has recently declined by 5% in a week and 9% over three months, raising questions about its valuation. Currently priced at €355.6, it is considered undervalued compared to a fair value of €406. The company is focusing on acquisitions and digital innovation to enhance growth and margins. However, it faces risks from competition and rising advertising costs. The current P/E ratio of 31x is above peers, suggesting a premium that investors must evaluate. The analysis encourages investors to consider alternatives and assess potential value in the market." datetime: "2026-05-14T14:10:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286430983.md) - [en](https://longbridge.com/en/news/286430983.md) - [zh-HK](https://longbridge.com/zh-HK/news/286430983.md) --- # Assessing L'Oréal (ENXTPA:OR) Valuation After Recent Share Price Weakness ## L'Oréal stock performance sets up fresh questions for long term holders L'Oréal (ENXTPA:OR) has drifted lower recently, with the share price down around 5% over the past week and about 9% over the past 3 months, inviting a closer look at the current valuation. See our latest analysis for L'Oréal. At the latest share price of €355.6, L'Oréal’s recent 7 day share price return of around 5% and 3 month share price return of about 9% both point to fading momentum. This aligns with a 1 year total shareholder return that is slightly negative and a modestly positive 5 year total shareholder return. If these moves have you rethinking where to put fresh capital, it could be a good moment to broaden your watchlist and check out 102 top founder-led companies So with the stock drifting and trading below some analyst targets, the key question now is whether L'Oréal is temporarily out of favour and offers value, or if the current price already reflects its future growth potential. ## Most Popular Narrative: 12.4% Undervalued With L'Oréal closing at €355.6 against a narrative fair value of about €406, the gap between price and projected worth has caught attention. > _Major capital allocation to acquisitions such as Medik8 and Color Wow and digital or AI driven innovation is expected to increase category leadership, fuel product differentiation, and raise future revenue and net margins. Operational efficiencies from global IT transformation and BETiq optimization are driving sustained SG&A and A&P cost discipline, allowing for reinvestment in high impact innovation and launches. This ultimately supports both operating margin and future earnings growth._ Read the complete narrative. Want to see what sits behind that premium narrative? It leans on steady top line expansion, thicker margins, and a rich future earnings multiple. Curious which specific forecasts support a fair value near €406 and a higher required P/E in a competitive personal care sector? The full narrative lays out the numbers and joins the dots for you. **Result: Fair Value of €406.15 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh up risks such as tougher competition in North Asia and China, as well as higher advertising costs that could pressure margins and growth expectations. Find out about the key risks to this L'Oréal narrative. ## Another Take: Multiples Paint a Tougher Picture While the narrative fair value of about €406 suggests upside, the current P/E of roughly 31x sits above both peers at 27.3x and the European personal products average at 16.5x, even though it is very close to a fair ratio of 31.3x. That mix of premium versus peers but near fair ratio raises a simple question for you: is this a quality premium you are comfortable paying, or a margin for error that feels a bit thin? See what the numbers say about this price — find out in our valuation breakdown. ENXTPA:OR P/E Ratio as at May 2026 ## Next Steps If the mixed signals so far leave you unsure, that is a useful signal in itself. Move quickly, review the data, and weigh the upside yourself by checking the 2 key rewards ## Looking for more investment ideas? If you are hesitating on what to do next, do not sit on the sidelines while other opportunities pass you by. Widen your search and compare alternatives. - Target potential value by scanning companies that combine quality fundamentals with attractive pricing using the 229 high quality undervalued stocks. - Prioritise resilience by reviewing companies with stronger financial footing through the solid balance sheet and fundamentals stocks screener (392 results). - Hunt for underfollowed opportunities by checking the screener containing 545 high quality undiscovered gems. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [LRLCY.US](https://longbridge.com/en/quote/LRLCY.US.md) ## Related News & Research - [Bernstein Keeps Their Hold Rating on L’Oreal (0NZM)](https://longbridge.com/en/news/286201078.md) - [L’Oreal shares surge after sales rise despite tough market conditions](https://longbridge.com/en/news/283793593.md) - [Assessing L'Oréal (ENXTPA:OR) Valuation After Q1 2026 Beat And €4b Kering Beauté Acquisition](https://longbridge.com/en/news/284274818.md) - [Armani could split 15% stake among L'Oreal, LVMH, EssilorLuxottica, report says](https://longbridge.com/en/news/285838017.md) - [Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness](https://longbridge.com/en/news/286895616.md)